518,482 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Nuveen LLC

Key Points

• Nuveen LLC acquired a significant stake in Pacira BioSciences, buying 518,482 shares valued at approximately $12.88 million, which represents about 1.12% of the company's total shares.
• Pacira BioSciences reported earnings of $0.74 per share for its last quarter, slightly beating analyst expectations, although revenue increased only 1.7% year-over-year.
• Analysts have rated Pacira BioSciences with a consensus of "Moderate Buy", with an average target price of $30.83.

Nuveen LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 518,482 shares of the company's stock, valued at approximately $12,884,000. Nuveen LLC owned 1.12% of Pacira BioSciences as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC raised its holdings in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares during the period. Ancora Advisors LLC acquired a new stake in Pacira BioSciences in the fourth quarter worth $26,000. US Bancorp DE raised its holdings in Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after purchasing an additional 537 shares during the period. Wealthquest Corp acquired a new stake in Pacira BioSciences in the first quarter worth $59,000. Finally, GAMMA Investing LLC raised its holdings in Pacira BioSciences by 112.8% in the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock worth $92,000 after purchasing an additional 1,958 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PCRX shares. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Truist Financial upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective on the stock in a report on Friday, July 25th. Needham & Company LLC dropped their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Pacira BioSciences presently has a consensus rating of "Moderate Buy" and an average target price of $30.83.

Pacira BioSciences Stock Up 0.5%

PCRX stock traded up $0.14 during midday trading on Wednesday, hitting $26.13. The company's stock had a trading volume of 908,801 shares, compared to its average volume of 814,279. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. Pacira BioSciences, Inc. has a twelve month low of $12.61 and a twelve month high of $27.64. The company's fifty day moving average price is $23.59 and its 200 day moving average price is $24.56. The stock has a market capitalization of $1.17 billion, a P/E ratio of -9.40 and a beta of 0.48.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. During the same quarter last year, the firm posted $0.96 EPS. The company's quarterly revenue was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Insider Transactions at Pacira BioSciences

In related news, Director Marcelo Bigal sold 4,912 shares of Pacira BioSciences stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the sale, the director owned 11,393 shares of the company's stock, valued at approximately $269,672.31. The trade was a 30.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Lauren Riker sold 5,578 shares of Pacira BioSciences stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. The trade was a 8.56% decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.